Top 5 Most Read RNS's on Vox Markets for Thursday 29th September 2022

Episode 924,  Sep 29, 06:44 AM

Top 5 Most Read RNS's on Vox Markets for Thursday 29th September 2022

5. Synairgen #SNG - Interim Results

Synairgen continues to explore the potential of SNG001 in three settings:

1. For use as a broad-spectrum antiviral for people hospitalised with severe viral lung infections;

2. In people hospitalised with COVID-19 and,

3. As a possible future pandemic preparedness option for government agencies.

4. Kodal Minerals #KOD - Bougouni Project DMS Development Opportunity

Capital development cost for the DMS plant and all associated infrastructure and commencement of mining is estimated at US$65 million, generating an estimated NPV7% of approximately US$557 million (US$420 million post-tax) and, based on full equity funding, a short payback of 2 months from commencement of operations.

3. Union Jack Oil #UJO - PEDL183 Competent Person’s Report by RPS Energy

Kirkham Abbey Best Case Gross Unrisked Contingent Technically Recoverable Sales Gas at West Newton is estimated to be 197.6 billion cubic feet.

2. Supply @ME Capital #SYME - 2022 Interim Results

Operating loss before acquisition related costs and impairment charges of £2.52m (2021: £1.46m) primarily as a result of increased headcount, higher cost base due to the acquisition of TradeFlow Capital Management in July 2021, and continued investment in operations to satisfy Inventory Funders requirements.

1. Avacta Group #AVCT - Interim Results for the Period Ended 30 June 2022

The first-in-human Phase I clinical trial (ALS-6000-101) of AVA6000, a FAPα-activated doxorubicin, progressed through the first and second cohorts (80 mg/m2 to 120 mg/m2 respectively) and initiated the third cohort at 160mg/m2.